In a pan­dem­ic boom call­back, David Li­u's pre­clin­i­cal gene edit­ing start­up de­buts on Nas­daq with $175M IPO

David Liu’s CRISPR 3.0 play will of­fi­cial­ly hit Nas­daq on Thurs­day.

Prime Med­i­cine priced its IPO raise with $175 mil­lion in new cash, the com­pa­ny an­nounced late Wednes­day, ex­pect­ing to of­fer a lit­tle more than 10 mil­lion shares that will de­but at $17 apiece. The move comes amid a large­ly frozen IPO mar­ket last­ing most of the year, but one that’s seen signs of thaw­ing re­cent­ly af­ter an­oth­er biotech, Third Har­mon­ic Bio, closed its ini­tial of­fer­ing at more than $210 mil­lion last month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER